Abstract:Gelagey Baye Temesgen, 1 Menakath Menon, 2 Solomon Tebeje Gizaw, 2 Bayu Wondimneh Yimenu, 1 Melaku Mekonen Agidew 3 1 Department of Biomedical Sciences, Debre Markos University, Debre Markos, Ethiopia; 2 Department of Medical Biochemistry School of Medicine, College of Health Sciences Addis Ababa University, Addis Ababa, Ethiopia; 3 Department of Medical Biochemistry, School of Medicine, Debre Tabor University, Debre Tabor, Ethiopia Correspondence: Gelagey Baye Temesgen Tel +251 918479703 Fax +251 587780673 Email Introduction: H. pylori are gram-negative, microaerophilic helical-shaped bacteria with multiple flagella and commonly exist in the stomach. This infection may cause significant mucosal inflammation and damage, leading to ulcers in the stomach. It can also affect organ systems external to the gastrointestinal tract. To assess cardiovascular risk factors and to predict cardiovascular disorders, we are evaluating and comparing lipid profile and inflammatory marker between H. pylori- positive and negative patients. Objective: To evaluate and compare lipid profile (TC; TG; LDL; HDL) and inflammatory marker (hs-CRP) in dyspeptic patients with and without H. pylori infection. Methods: Comparative cross-sectional study was conducted from September 2020 to January 2021 at Debre Markos Referral Hospital, Debre Markos Health Center, and Hidassie Health Center, Ethiopia. Each of 50 H. pylori -positive and negative dyspeptic patients were studied. The data were checked for completeness and analyzed by SPSS version 25.0 Software. A p-value < 0.05 was considered statistically significant. Results: Serum mean high-density lipoprotein (HDL) values were 37.54 ± 7.98 mg/dL and 43.12 ± 7.86 mg/dL (p < 0.05) for H. pylori -positive and negative dyspeptic patients, respectively, and median serum high sensitive C reactive protein (hs-CRP) levels were 6.29 mg/L (1.66– 41.34) and 3.35 mg/L (0.39– 10.01) (p < 0.05) for H. pylori -positive and negative dyspeptic patients, respectively. Conclusion: H. pylori infection significantly alters serum high-density lipoprotein (HDL) and high sensitive C reactive protein (hs-CRP) levels in dyspeptic patients, as a result, increase the potential risk of cardiovascular diseases. Keywords: H. pylori , dyspepsia, lipid profile, hs-CRP, inflammation, cardiovascular diseases The Genus Helicobacter has different species but only H. pylori can survive in human beings. Other species of helicobacter can survive in different animals. 1 H. pylori are a spiral-shaped, gram-negative, microaerophilic rod with 4–7 flagella. The flagella help in the settlement of the bacterium to the gastric mucosa layer. 2 H. pylori produce outer membrane vesicles that contain different virulence factors encompassing cell-bound components, secreted molecules, and antigens that could be injected into a host cell by the type IV secretion system (T4SS) or direct secretion of soluble compounds to the gastric area. Outer membrane vesicles are described as 20–300 nm blebs, which are secreted during the logarithmic phase of Gram-negative bacteria growth. Outer membrane vesicles can be crossing the cellular barrier which is the effective way of H. pylori antigens and virulence factors translocation via the gastric mucosa towards the immune cells. H. pylori outer membrane vesicles contains lipopolysaccharide, Vacuolating cytotoxin gene A (VacA), Cytotoxin associated gene A (CagA), blood group antigen-binding adhesin, sialic acid-binding adhesin, outer inflammatory protein A, H. pylori neutrophil-activating protein, adherence associated lipoprotein, and urease. Those proteins and lipids are involved in the pathogenesis of H. pylori infection. 3 The virulence factors of H. pylori can cause gastric inflammation, disruption of the gastric mucosal barrier, and extra gastric effect. 4 Chronic inflammations are the critical component of the disease process of H. pylori , which is the initial step starting from superficial gastritis to chronic gastritis, intestinal metaplasia to dysplasia, and until invasive adenocarcinoma. 5 The virulence factors of H. Pylori have a greater contribution to the disease process by inducing gastric inflammation and disruption of the gastric mucosal barrier. H. pylori promote gastric inflammation by stimulating interleukin (IL-8) secretion from the gastric cell, inducing neutrophil-endothelial cell interactions, activating platelet-activating factor, injecting the lipopol -Abstract Truncated-

Helicobacter pylori antigens, acetylsalicylic acid, LDL and 7-ketocholesterol - their potential role in destabilizing the gastric epithelial cell barrier. An in vitro model of Kato III cells.

The effect of Helicobacter pylori infection and different H. pylori components on the proliferation and apoptosis of gastric epithelial cells and fibroblasts

Helicobacter Pylori Lipopolysaccharide: Biological Activities in Vitro and in Vivo, Pathological Correlation to Human Chronic Gastritis and Peptic Ulcer.

Pathophysiology and clinical relevance of Helicobacter pylori

Helicobacter pylori Type IV Secretion System and Its Adhesin Subunit, CagL, Mediate Potent Inflammatory Responses in Primary Human Endothelial Cells

[Helicobacter Pylori Infection Enhances Atherosclerosis in High-Cholesterol Diet Fed C57BL/6 Mice].

Helicobacter pylori infection alters gastric and tongue coating microbial communities

Chemical synthesis of Helicobacter pylori lipopolysaccharide partial structures and their selective proinflammatory responses.

Helicobacter pylori disrupts gastric mucosal homeostasis by stimulating macrophages to secrete CCL3

Helicobacter pylori Infection Acts Synergistically with a High-Fat Diet in the Development of a Proinflammatory and Potentially Proatherogenic Endothelial Cell Environment in an Experimental Model

N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection

Helicobacter Pylori Infection And Administration Of Non-Steroidal Anti-Inflammatory Drugs Down-Regulate The Expression Of Gastrokine-1 In Gastric Mucosa

Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice

Gastric Parietal Cell Physiology and Helicobacter pylori–Induced Disease

Evaluation of Lipid Profile and Inflammatory Marker in Patients with Gastric Helicobacter pylori Infection, Ethiopia

Immunostimulatory Membrane Proteins Potentiate H. Pylori-Induced Carcinogenesis by Enabling CagA Translocation

Probing the expression and adhesion of glycans involved in Helicobacter pylori infection

Crosstalk between Helicobacter pylori and gastric epithelial cells is impaired by docosahexaenoic acid

The Role of Immunoglobulin G (IgG), IgA and IgE—Antibodies against Helicobacter pylori in the Development of Oxidative Stress in Patients with Chronic Gastritis

Immunobiological effects of lipopolysaccharide derived from Helicobacter pylori and influence of a proton pump inhibitor lansoprazole on human polymorphonuclear leukocytes

CagA+Helicobacter pylori, Not CagA–Helicobacter pylori, Infection Impairs Endothelial Function Through Exosomes-Mediated ROS Formation